Acute Myeloid Leukemia | Topics

Phase 1/2 Trial of Frontline Eprenetapopt Plus Venetoclax and Azacitidine for TP53-Mutant AML Meets End Point
June 20, 2021

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

Early Promise of Anti–CLL-1 CAR T-Cell Therapy Reported in Pediatric AML
June 06, 2021

Results of a phase 1/2 trial presented at the 2021 ASCO Annual Meeting show the feasibility of an approach targeting CLL-1 cells in pediatric patients with relapsed or refractory acute myeloid leukemia.

Novel Therapeutic Regimen Achieves Responses in Elderly Patients with AML/MDS
June 01, 2021

Most elderly patients with acute myeloid leukemia and myelodysplastic syndromes cannot undergo intensive chemotherapy, but more than half of the patients in a new study responded to a regimen of ultra low–dose decitabine and low-dose cytarabine with G-CSF.